Breakthrough Therapy Designations: February 2026 Analysis

Updated on March 20, 2026 | Written by PatSnap Team

Twelve drugs received Breakthrough Therapy designation (BTD) in February 2026 — 6 from the FDA and 6 from China’s NMPA. Oncology accounted for 7 of the 12 grants. Three KRAS-targeted agents, two ADCs, and two rare disease programs were among the month’s most significant designations.

All data sourced from PatSnap Synapse.

What Is Breakthrough Therapy Designation?

Breakthrough Therapy designation is granted by the FDA (and equivalently by the NMPA in China) when preliminary clinical evidence indicates that a drug may offer substantial improvement over existing therapies on a clinically significant endpoint for a serious condition. Benefits include:

• Intensive FDA guidance throughout development
• Rolling NDA/BLA review (review begins before the complete application is submitted)
• Eligibility for priority review upon submission
• Senior FDA leadership involvement in review

The FDA introduced BTD in 2012 under the FDA Safety and Innovation Act. China’s NMPA introduced an equivalent program in 2020. For a full explanation of how BTD compares to other expedited pathways, see FDA expedited pathways explained.

February 2026 BTD Summary

Oncology: Seven BTDs Across Four Tumor Types

Lung cancer dominated (4 BTDs)

NSCLC and SCLC together accounted for four Breakthrough Therapy grants this month — more than any other tumor type.

Calderasib (MSD China) and GFH-375 (Genfleet) both target KRAS mutations in NSCLC — G12C and G12D respectively. These designations, alongside Sosimerasib’s NMPA approval, confirm China as the most active KRAS regulatory jurisdiction outside the US in 2026. See the full KRAS G12C/G12D pipeline analysis for competitive context.

WSD-0922 (Wayshine Biopharm) targets EGFR C797S — the tertiary resistance mutation that emerges in NSCLC patients who progress on third-generation EGFR inhibitors like osimertinib. C797S has no approved therapy; WSD-0922’s BTD is the first major regulatory signal in this resistance mechanism.

Pembrolizumab (MSD China) received NMPA BTD for KRAS G12C-mutant NSCLC — a combination rationale reflecting emerging evidence that KRAS G12C tumors may have increased immunogenicity and PD-L1 expression, making PD-1 + KRAS G12C inhibitor combinations a rational strategy.

Zocilurtatug pelitecan (Zai Lab) is a bispecific ADC targeting DLL3 (expressed on SCLC tumor cells) conjugated to a topoisomerase I inhibitor payload. DLL3 is highly expressed in SCLC, an aggressive cancer with very limited treatment options after platinum-based chemotherapy. This is Zai Lab’s second major ADC BTD in the past 18 months.

Breast cancer: PIK3CA mutation targeting

Zovegalisib (Relay Therapeutics) received FDA BTD for PIK3CA-mutant HR-positive/HER2-negative breast cancer — specifically targeting three activating PIK3CA mutations (H1047X, E542K, E545K) that are collectively present in approximately 40% of HR+/HER2- breast cancers. PIK3CA mutations drive resistance to CDK4/6 inhibitors and endocrine therapy. Alpelisib (Piqray) is the only approved PIK3CA inhibitor in this setting; zovegalisib’s differentiation likely lies in selectivity profile and tolerability, as alpelisib carries significant hyperglycemia risk.

Esophageal and prostate cancer: ADC expansion

MHB088C (Qilu Pharmaceutical) is a CD276 (B7-H3)-targeted ADC for esophageal squamous cell carcinoma and metastatic castration-resistant prostate cancer. B7-H3 is broadly overexpressed across many solid tumors, and multiple ADC programs targeting this antigen are in development globally. Qilu’s BTD in two distinct tumor types with a single agent reflects the pan-tumor potential of B7-H3 targeting.

Tracking all Breakthrough Therapy designated programs across oncology targets — ADCs, bispecifics, small molecules — in a single view? Explore BTD pipeline data in PatSnap Synapse →

Rare Disease and Neurology: Three BTDs

Want to track the full competitive landscape, patent estate, and clinical pipeline for this target? Search this target in PatSnap →

NGN-401 — AAV gene therapy for Rett Syndrome

NGN-401 (Neurogene) is an AAV9-based gene therapy delivering a regulated copy of MECP2 — the gene mutated in Rett syndrome, a severe X-linked neurodevelopmental disorder affecting almost exclusively females. MECP2 overexpression is itself toxic, making dosing precision critical; Neurogene’s approach uses a microRNA-based regulatory element to control MECP2 expression levels. FDA BTD was granted based on early Phase 1/2 data showing meaningful improvement in Rett syndrome severity scores. For disease background, see NORD’s Rett syndrome information.

Nomlabofusp — frataxin fusion protein for Friedreich Ataxia

Nomlabofusp (Larimar Therapeutics) is a fusion protein that delivers frataxin — the mitochondrial protein deficient in Friedreich Ataxia — directly into cells via a cell-penetrating peptide. Friedreich Ataxia is caused by GAA trinucleotide repeat expansion in the FXN gene, leading to frataxin deficiency, mitochondrial iron accumulation, and progressive neurodegeneration. Omaveloxolone (Skyclarys) is the only approved treatment for FA; nomlabofusp’s mechanism of directly replacing the deficient protein offers a fundamentally different approach. BTD was granted based on Phase 2 data showing functional improvements.

Rilzabrutinib — BTK inhibition in wAIHA

Rilzabrutinib (Sanofi) received BTD for warm autoimmune hemolytic anemia, making it the first BTK inhibitor to receive this designation for a primary autoimmune hematological indication. For full mechanistic analysis and competitive context, see the Rilzabrutinib drug profile.

Luvesilocin — 5-HT2A agonism for Postpartum Depression

Luvesilocin (Reunion Neuroscience) is a selective 5-HT2A agonist for postpartum depression (PPD) — a condition affecting approximately 1 in 7 new mothers globally. The 5-HT2A mechanism in depression relates to neuroplasticity and synaptic remodelling via BDNF signalling, distinct from SSRI/SNRI mechanisms. Brexanolone (Zulresso) and zuranolone (Zurzuvae) are approved specifically for PPD via neuroactive steroid/GABA mechanisms. Luvesilocin represents a different pharmacological approach; BTD was granted on the strength of Phase 2 data. For PPD epidemiology context, see WHO mental health resources.

Amivantamab + Hyaluronidase — Bispecific Antibody in Head and Neck Cancer

Amivantamab-VMJM/Hyaluronidase (Johnson & Johnson) received BTD for advanced head and neck squamous cell carcinoma (HNSCC). Amivantamab is a bispecific antibody targeting both EGFR and c-Met (MET), co-administered with hyaluronidase to enable subcutaneous delivery. It is already FDA-approved for EGFR-mutant NSCLC (Rybrevant). The BTD in HNSCC — a tumor type with high EGFR expression — represents an indication expansion leveraging the dual-target mechanism.

Key Trends in February’s BTD Cohort

China’s NMPA BTD program is now generating international-calibre pipeline signals. Six of 12 BTDs came from NMPA — and several (GFH-375, WSD-0922, MHB088C) represent genuinely novel biology without direct FDA-approved precedent in the same indication.

ADCs are diversifying beyond HER2 and TROP2. MHB088C targets CD276 (B7-H3) and Zocilurtatug pelitecan targets DLL3 — neither of which has an approved ADC. The modality continues to expand into previously intractable tumor biology.

Precision oncology is entering resistance mutation space. WSD-0922 targeting EGFR C797S and Zovegalisib targeting PIK3CA activating mutations both address acquired or primary resistance in established targeted therapy patient populations — a sign that the field is moving from first-line targeting to managing resistance.

PatSnap Synapse lets you filter every Breakthrough Therapy designation by target, indication, developer, and timeline — and connects each drug to its patent estate and clinical trial history. Monitor BTD activity on Synapse →

Monthly drug approvals, ERP designations, competitor pipeline shifts — PatSnap Eureka helps drug development and BD teams stay ahead of the curve. Try now →

Further Reading

• Expedited review pathways overview — February 2026
• Global drug approvals roundup — February 2026
• ADC pipeline analysis — February 2026
• KRAS G12C/G12D inhibitor pipeline — 2026
• Rilzabrutinib: BTK inhibition in wAIHA
• FDA expedited pathways explained

Data sourced by PatSnap. This post is for informational purposes only.